ReviewCancer drug resistance (Alhambra, Calif.)2025

Osimertinib acquired resistance among patients with EGFR-mutated NSCLC: from molecular mechanisms to clinical therapeutic strategies.

Ren Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.